Binding of the monomeric form of C-reactive protein to enzymatically-modified low-density lipoprotein: Effects of phosphoethanolamine

Clinica Chimica Acta

Volumn 406, Issue 1-2, 2009, Pages 151-155

  Singh, Sanjay K ^a   Suresh, Madathilparambil V ^a   Hammond Jr , David J ^a   Rusiñol, Antonio E ^a   Potempa, Lawrence A ^b   Agrawal, Alok ^a  

^a East Tennessee State University   (United States)

^b Acphazin Inc   (United States)

Author keywords

C reactive protein; Enzymatically modified low density lipoprotein; Monomeric C reactive protein; Phosphoethanolamine; Pneumococcal C polysaccharide

Indexed keywords

C REACTIVE PROTEIN; LIGAND; LOW DENSITY LIPOPROTEIN; PHOSPHOETHANOLAMINE; PHOSPHORYLCHOLINE; PNEUMOCOCCUS POLYSACCHARIDE;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MODIFICATION; PROTEIN PURIFICATION; PROTEIN TARGETING;

ANIMALS; C-REACTIVE PROTEIN; ETHANOLAMINES; HUMANS; LIPOPROTEINS, LDL; POLYSACCHARIDES, BACTERIAL; PROTEIN BINDING; STEROL ESTERASE;

EID: 67650224004     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.06.018     Document Type: Article

References (51)

1. Singh S.K., Suresh M.V., Voleti B., and Agrawal A. The connection between C-reactive protein and atherosclerosis. Ann Med 40 (2008) 110-120
2. Black S., Kushner I., and Samols D. C-reactive protein. J Biol Chem 279 (2004) 48487-48490
3. Peisajovich A., Marnell L., Mold C., and Du Clos T.W. C-reactive protein at the interface between innate immunity and inflammation. Expert Rev Clin Immunol 4 (2008) 379-390
4. Shrive A.K., Cheetham G.M.T., Holden D., et al. Three dimensional structure of human C-reactive protein. Nat Struct Biol 3 (1996) 346-354
5. Volanakis J.E., and Wirtz K.W.A. Interaction of C-reactive protein with artificial phosphatidylcholine bilayers. Nature 281 (1979) 155-157
6. Schwalbe R.A., Dahlbäck B., Coe J.E., and Nelsestuen G.L. Pentraxin family of proteins interacts specifically with phosphorylcholine and/or phosphorylethanolamine. Biochemistry 31 (1992) 4907-4915
7. Agrawal A., Simpson M.J., Black S., Carey M.P., and Samols D. A C-reactive protein mutant that does not bind to phosphocholine and pneumococcal C-polysaccharide. J Immunol 169 (2002) 3217-3222
8. Schwedler S.B., Filep J.G., Galle J., Wanner C., and Potempa L.A. C-reactive protein: a family of proteins to regulate cardiovascular function. Am J Kidney Dis 47 (2006) 212-222
9. Boncler M., and Watala C. Regulation of cell function by isoforms of C-reactive protein: a comparative analysis. Acta Biochim Pol 56 (2009) 17-31
10. Potempa L.A., Siegel J.N., Fiedel B.A., Potempa R.T., and Gewurz H. Expression, detection and assay of a neoantigen (neo-CRP) associated with a free, human C-reactive protein subunit. Mol Immunol 24 (1987) 531-541
11. Khreiss T., József L., Potempa L.A., and Filep J.G. Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation 109 (2004) 2016-2022
12. Ji S.R., Wu Y., Potempa L.A., Liang Y.H., and Zhao J. Effect of modified C-reactive protein on complement activation: a possible complement regulatory role of modified or monomeric C-reactive protein in atherosclerotic lesions. Arterioscler Thromb Vasc Biol 26 (2006) 935-941
13. Wang H.W., Wu Y., Chen Y., and Sui S.F. Polymorphism of structural forms of C-reactive protein. Int J Mol Med 9 (2002) 665-671
14. Ji S.R., Wu Y., Potempa L.A., Qiu Q., and Zhao J. Interactions of C-reactive protein with low-density lipoproteins: implications for an active role of modified C-reactive protein in atherosclerosis. Int J Biochem Cell Biol 38 (2006) 648-661
15. Taylor K.E., and van den Berg C.W. Structural and functional comparison of native pentameric, denatured monomeric and biotinylated C-reactive protein. Immunology 120 (2007) 404-411
16. Hakobyan S., Harris C.L., van den Berg C.W., et al. Complement factor H binds to denatured rather than to native pentameric C-reactive protein. J Biol Chem 283 (2008) 30451-30460
17. Kinoshita C.M., Ying S.C., Hugli T.E., et al. Elucidation of a protease-sensitive site involved in the binding of calcium to C-reactive protein. Biochemistry 28 (1989) 9840-9848
18. Suresh M.V., Singh S.K., and Agrawal A. Interaction of calcium-bound C-reactive protein with fibronectin is controlled by pH: in vivo implications. J Biol Chem 279 (2004) 52552-52557
19. Wang H.W., and Sui S.F. Dissociation and subunit rearrangement of membrane-bound human C-reactive proteins. Biochem Biophys Res Comm 288 (2001) 75-79
20. m. FASEB J 21 (2007) 284-294
21. Ji S.R., Ma L., Bai C.J., et al. Monomeric C-reactive protein activates endothelial cells via interaction with lipid raft microdomains. FASEB J 23 (2009) 1806-1816
22. Rees R.F., Gewurz H., Siegel J.N., Coon J., and Potempa L.A. Expression of a C-reactive protein neoantigen (neo-CRP) in inflamed rabbit liver and muscle. Clin Immunol Immunopathol 48 (1988) 95-107
23. Diehl E.E., Haines III G.K., Radosevich J.A., and Potempa L.A. Immunohistochemical localization of modified C-reactive protein antigen in normal vascular tissue. Am J Med Sci 319 (2000) 79-83
24. Schwedler S.B., Guderian F., Dämmrich J., Potempa L.A., and Wanner C. Tubular staining of modified C-reactive protein in diabetic chronic kidney disease. Nephrol Dial Transplant 18 (2003) 2300-2307
25. Kiefer C.R., McKenney J.B., Trainor J.F., and Snyder L.M. Pulse pressure-driven neutral lipid accumulation and correlative proinflammatory markers of accelerated atherogenesis. Atherosclerosis 183 (2005) 17-24
26. Slevin M, Matou-Nasri S, Turu M, et al. Modified C-reactive protein is expressed by stroke neovessels and is a potent activator of angiogenesis in vitro. Brain Pathol in press, doi:10.1111/j.1750-3639.2008.00256.x.
27. Agrawal A., and Bhattacharya S. Possible role of C-reactive protein in detoxication of mercury. Indian J Exp Biol 28 (1990) 638-641
28. Ruleva N.Y., Lyukova T.K., Tarabarko N.V., Komolov I.S., and Domogatskii S.P. Structure of C-reactive protein excreted in urine during acute rejection episodes. Bull Exp Biol Med 135 (2003) 250-252
29. Wetterö J., Nilsson L., Jonasson L., and Sjöwall C. Reduced serum levels of autoantibodies against monomeric C-reactive protein (CRP) in patients with acute coronary syndrome. Clin Chim Acta 400 (2009) 128-131
30. Bhakdi S., Dorweiler B., Kirchmann R., et al. On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety. J Exp Med 182 (1995) 1959-1971
31. Bhakdi S., Torzewski M., Klouche M., and Hemmes M. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol 19 (1999) 2348-2354
32. Taskinen S., Kovanen P.T., Jarva H., Meri S., and Pentikainen M.O. Binding of C-reactive protein to modified low-density-lipoprotein particles: identification of cholesterol as a novel ligand for C-reactive protein. Biochem J 367 (2002) 403-412
33. Biró A., Thielens N.M., Cervenák L., Prohászka Z., Füst G., and Arlaud G.J. Modified low density lipoproteins differentially bind and activate the C1 complex of complement. Mol Immunol 44 (2006) 1169-1177
34. Singh S.K., Suresh M.V., Prayther D.C., Moorman J.P., Rusinol A.E., and Agrawal A. C-reactive protein-bound enzymatically modified low-density lipoprotein does not transform macrophages into foam cells. J Immunol 180 (2008) 4316-4322
35. Agrawal A. Therapeutic potential of phosphoethanolamine-bound C-reactive protein in atherosclerosis. Future Lipidol 3 (2008) 599-602
36. Heuertz R.M., Schneider G.P., Potempa L.A., and Webster R.O. Native and modified C-reactive proteins bind different receptors on human neutrophils. Int J Biochem Cell Biol 37 (2005) 320-335
37. Boguslawski G., McGlynn P.W., Potempa L.A., Filep J.G., and Labarrere C.A. Conduct unbecoming: C-reactive protein interactions with a broad range of protein molecules. J Heart Lung Transplant 26 (2007) 705-713
38. Agrawal A., Singh S.K., Thompson J.A., Hammond D.J., and Rusinol A.E. Requirements for the binding of C-reactive protein to oxidized low-density lipoprotein. FASEB J 23 (2009) 1006.2
39. Hammond D.J., Singh S.K., Suresh M.V., Pangburn M.K., and Agrawal A. Requirements for the binding of C-reactive protein to complement factor H. J Immunol 182 (2009) 134.60
40. Singh S.K., Suresh M.V., Prayther D.C., Moorman J.P., Rusinol A.E., and Agrawal A. Phosphoethanolamine-complexed C-reactive protein: a pharmacological-like macromolecule that binds to native low-density lipoprotein in human serum. Clin Chim Acta 394 (2008) 94-98
41. Torzewski M., Suriyaphol P., Paprotka K., et al. Enzymatic modification of low-density lipoprotein in the arterial wall: a new role for plasmin and matrix metalloproteinases in atherogenesis. Arterioscler Thromb Vasc Biol 24 (2004) 2130-2136
42. Brown A.J., Leong S.L., Dean R.T., and Jessup W. 7-Hydroperoxycholesterol and its products in oxidized low density lipoprotein and human atherosclerotic plaque. J Lipid Res 38 (1997) 1730-1745
43. Torzewski M., Rist C., Mortensen R.F., et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 20 (2000) 2094-2099
44. Sun H., Koike T., Ichikawa T., et al. C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance. Am J Pathol 167 (2005) 1139-1148
45. Reynolds G.D., and Vance R.P. C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. Arch Pathol Lab Med 111 (1987) 265-269
46. Samberg N.L., Bray R.A., Gewurz H., Landay A.L., and Potempa L.A. Preferential expression of neo-CRP epitopes on the surface of human peripheral blood lymphocytes. Cell Immunol 116 (1988) 86-98
47. Schwedler S.B., Amann K., Wernicke K., et al. Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockout mice. Circulation 112 (2005) 1016-1023
48. Kovacs A., Tornvall P., Nilsson R., Tegnér J., Hamsten A., and Björkegren J. Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia. Proc Natl Acad Sci USA 104 (2007) 13768-13773
49. Harrington J.M., Chou H.T., Gutsmann T., et al. Membrane activity of a C-reactive protein. FEBS Lett 583 (2009) 1001-1005
50. Shrive A.K., Burns I., Chou H.T., Stahlberg H., Armstrong P.B., and Greenhough T.J. Crystal structures of Limulus SAP-like pentraxin reveal two molecular aggregations. J Mol Biol 386 (2009) 1240-1254
51. 125I-labeled modified C-reactive protein in CD-1 mice. Drug Metab Disp 26 (1998) 977-981